Literature DB >> 19790132

Clinical and genetic factors predictive of mortality in early systemic sclerosis.

Shervin Assassi1, Deborah Del Junco, Kari Sutter, Terry A McNearney, John D Reveille, Andrew Karnavas, Pravitt Gourh, Rosa M Estrada-Y-Martin, Michael Fischbach, Frank C Arnett, Maureen D Mayes.   

Abstract

OBJECTIVE: To investigate the clinical and genetic variables at initial presentation that predict survival in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS) cohort.
METHODS: GENISOS is a prospective, observational study of a multiethnic early systemic sclerosis (SSc) cohort. To date, a total of 250 patients have been enrolled. In addition to clinical and laboratory data, electrocardiograms (EKGs), chest radiographs, and pulmonary function tests have been obtained from each patient. A modified Rodnan skin thickness score, HLA class II genotyping, and a Medsger Damage Index also have been collected. We performed multivariable analyses utilizing the Cox regression following a purposeful model building strategy.
RESULTS: The study analyzed 122 white, 47 African American, and 71 Hispanic SSc patients with an average disease duration of 2.6 years at enrollment. At the time of analysis, 52 (20.8%) of the 250 patients had died. In the final multivariable model excluding HLA genes, 7 variables emerged as significant predictors of mortality: age > or =65 years at enrollment, forced vital capacity <50% predicted, clinically significant arrhythmia on EKG, absence of anticentromere antibodies, hypertension, chest radiograph suggestive of pulmonary fibrosis, and low body mass index (BMI). In separate modeling that included HLA genes, HLA alleles DRB1*0802 and DQA1*0501 were significant predictors of mortality in addition to the predictors mentioned above.
CONCLUSION: A limited number of variables collected at presentation, including BMI, are able to predict mortality in patients with early SSc. In addition, some of the HLA genes associated with SSc susceptibility are useful for predicting SSc outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19790132      PMCID: PMC2883167          DOI: 10.1002/art.24734

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  40 in total

Review 1.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies.

Authors: 
Journal:  Lancet       Date:  2004-01-10       Impact factor: 79.321

2.  HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome.

Authors:  P Langevitz; D Buskila; D D Gladman; G A Darlington; V T Farewell; P Lee
Journal:  Br J Rheumatol       Date:  1992-09

3.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

4.  Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit.

Authors:  C Bryan; C Knight; C M Black; A J Silman
Journal:  Arthritis Rheum       Date:  1999-12

5.  Survival in scleroderma.

Authors:  R Bennett; R Bluestone; P J Holt; E G Bywaters
Journal:  Ann Rheum Dis       Date:  1971-11       Impact factor: 19.103

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

7.  Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls.

Authors:  Frank C Arnett; Pravitt Gourh; Sanjay Shete; Chul W Ahn; Robert E Honey; Sandeep K Agarwal; Filemon K Tan; Terry McNearney; Michael Fischbach; Marvin J Fritzler; Maureen D Mayes; John D Reveille
Journal:  Ann Rheum Dis       Date:  2009-07-12       Impact factor: 19.103

8.  Predictors of survival in systemic sclerosis (scleroderma).

Authors:  R D Altman; T A Medsger; D A Bloch; B A Michel
Journal:  Arthritis Rheum       Date:  1991-04

9.  Initial predictors of survival in patients with systemic sclerosis (scleroderma).

Authors:  J Kaburaki; C C Lee; M Kuwana; T Tojo; Y Ikeda; M Takano; Y Funatsu
Journal:  Keio J Med       Date:  1992-09

10.  Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients.

Authors:  T A Medsger; A T Masi; G P Rodnan; T G Benedek; H Robinson
Journal:  Ann Intern Med       Date:  1971-09       Impact factor: 25.391

View more
  36 in total

1.  Determinants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS cohort.

Authors:  Roozbeh Sharif; Maureen D Mayes; Perry M Nicassio; Emilio B Gonzalez; Hilda Draeger; Terry A McNearney; Rosa M Estrada-Y-Martin; Deepthi K Nair; John D Reveille; Frank C Arnett; Shervin Assassi
Journal:  Semin Arthritis Rheum       Date:  2011-03-22       Impact factor: 5.532

2.  HLA-DRB1*0407 and *1304 are risk factors for scleroderma renal crisis.

Authors:  Binh Nguyen; Maureen D Mayes; Frank C Arnett; Deborah del Junco; John D Reveille; Emilio B Gonzalez; Hilda T Draeger; Marilyn Perry; Amir Hendiani; Kiran K Anand; Shervin Assassi
Journal:  Arthritis Rheum       Date:  2011-02

Review 3.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

4.  IRF5 polymorphism predicts prognosis in patients with systemic sclerosis.

Authors:  Roozbeh Sharif; Maureen D Mayes; Filemon K Tan; Olga Y Gorlova; Laura Kathleen Hummers; Ami A Shah; Daniel E Furst; Dinesh Khanna; Javier Martin; Lara Bossini-Castillo; Emilio B Gonzalez; Jun Ying; Hilda Torres Draeger; Sandeep K Agarwal; John D Reveille; Frank C Arnett; Fredrick M Wigley; Shervin Assassi
Journal:  Ann Rheum Dis       Date:  2012-03-22       Impact factor: 19.103

Review 5.  Hispanic mortality paradox: a systematic review and meta-analysis of the longitudinal literature.

Authors:  John M Ruiz; Patrick Steffen; Timothy B Smith
Journal:  Am J Public Health       Date:  2013-01-17       Impact factor: 9.308

6.  Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis.

Authors:  Roozbeh Sharif; Marvin J Fritzler; Maureen D Mayes; Emilio B Gonzalez; Terry A McNearney; Hilda Draeger; Murray Baron; Daniel E Furst; Dinesh K Khanna; Deborah J del Junco; Jerry A Molitor; Elena Schiopu; Kristine Phillips; James R Seibold; Richard M Silver; Robert W Simms; Marilyn Perry; Carlos Rojo; Julio Charles; Xiaodong Zhou; Sandeep K Agarwal; John D Reveille; Shervin Assassi; Frank C Arnett
Journal:  J Rheumatol       Date:  2011-05-15       Impact factor: 4.666

7.  Validation of the ACR/EULAR classification criteria for systemic sclerosis in patients with early scleroderma.

Authors:  Farley Carvalho Araújo; Cíntia Zumstein Camargo; Cristiane Kayser
Journal:  Rheumatol Int       Date:  2017-08-17       Impact factor: 2.631

Review 8.  Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?

Authors:  Chandra Mohan; Shervin Assassi
Journal:  BMJ       Date:  2015-11-26

9.  Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.

Authors:  Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Res Ther       Date:  2010-09-02       Impact factor: 5.156

Review 10.  Determinants of mortality in systemic sclerosis: a focused review.

Authors:  Dilli Ram Poudel; Divya Jayakumar; Abhijeet Danve; Shiv Tej Sehra; Chris T Derk
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.